天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Toggle Nav
Close
  • Menu
  • Setting

GW501516

Catalog No.
A4309
PPARδ agonist,selective and potent
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$61.00
In stock
5mg
$55.00
In stock
10mg
$94.00
In stock
50mg
$193.00
In stock
100mg
$286.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

GW501516 is subtype-selective small-molecule agonist of peroxisome proliferator-activated receptor δ (PPARδ) with Ki value of 1.1nM [1].

GW501516 is discovered by combinatorial chemistry and structure-based drug design to use as an ideal chemical tool to study the function of the ubiquitously expressed PPARδ. In the cell-based transfection assay, it induces expression of a GAL4-responsive reporter gene with EC50 value of 1.2nM. GW501516 shows more than 1000-fold selective for PPARδ over other subtypes. PPARδ is expressed in many tissues that contribute to cholesterol flux, and is a RXR of partner. As an agonist of PPARδ, GW501516 is found to increase the expression of ABCA1 as well as the apoA1-specific cholesterol efflux. In primate model of human metabolic disease, GW501516 increases the level of HDLc and lowers the fasting triglycerides. GW501516 also produces fewer, yet larger, LDL and VLDL particles results in a less atherogenic lipid composition. Furthermore, GW501516 partially corrects the hyperinsulinemia in primates without adverse effects on glycemic control [1, 2].

References:
[1] Wei ZL, Kozikowski AP. A short and efficient synthesis of the pharmacological research tool GW501516 for the peroxisome proliferator-activated receptor delta. J Org Chem. 2003 Nov 14;68(23):9116-8.
[2] Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5306-11.

Product Citation

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt453.5
Cas No.317318-70-0
FormulaC21H18F3NO3S2
Solubilityinsoluble in H2O; ≥18.05 mg/mL in DMSO; ≥44.6 mg/mL in EtOH
Chemical Name2-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid
SDFDownload SDF
Canonical SMILESCC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=CC=C(C=C3)C(F)(F)F)C)OCC(=O)O
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment:[1]

Cell lines

THP1 macrophages, 1BR3N human skin fibroblasts and FHS74 human intestinal cells

Reaction Conditions

100 nM GW501516

Applications

In macrophages, fibroblasts, and intestinal cells, GW501516 increased expression of the reverse cholesterol transporter ATP-binding cassette A1 (ABCA1) and induced apolipoprotein A1-specific cholesterol efflux. These results suggest that GW501516 may promote cholesterol efflux from multiple tissues by increasing expression of the reverse cholesterol transporter ABCA1.

Animal experiment:[2]

Animal models

A rat model of non-alcoholic fatty liver disease induced by a high-fat diet

Dosage form

10 mg/kg

Once daily by oral route for 4 weeks

Applications

After 4 weeks of treatment with GW501516, the hepatosomatic index was almost reduced to the level of the normal control group. In addition, a significant decrease in body mass index was observed in the rats that were treated with GW501516 for 4 weeks. GW501516 was found to alleviate non-alcoholic fatty liver disease by modulating glucose and fatty acid metabolic enzymes in a rat model.

Note

The technical data provided above is for reference only.

References:

1. Oliver WR Jr, Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98(9): 5306-5311.

2. Li X, Li J, Lu X, et al. Treatment with PPARδ agonist alleviates non-alcoholic fatty liver disease by modulating glucose and fatty acid metabolic enzymes in a rat model. International Journal of Molecular Medicine, 2015, 36(3): 767-775.

Biological Activity

Description GW501516 is a selective and potent agonist of PPARβ with EC50 value of 1.1 nM.
Targets PPARβ          
IC50 1.1 nM (EC50)          

Quality Control

Chemical structure

GW501516

Related Biological Data

GW501516